SWI Initiates Coverage on CytomX (CTMX)
We are living in a new world order today, no matter which side of that order you have positioned yourself. The market has not crashed, as predicted by many, so we can breath a little easier. To keep our world in order and stable, we have initiated coverage on what we believe to be a company worthwhile following and should be generating a solid return over time. In regards to the new world order, good luck to all of us.

 Probody Technology Platform

CytomX is an oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on its Probody technology platform. The company uses the platform to create proprietary cancer immunotherapies against clinically-validated targets, as well as to develop first-in-class investigational cancer therapeutics against novel targets. CytomX believes that its Probody platform has the potential to improve the combined efficacy and safety profile of monoclonal antibody modalities, including cancer immunotherapies, antibody drug conjugates and T-cell-recruiting bispecific antibodies. Probody therapeutics are designed to take advantage of unique conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.  The company‚Äôs investigational Probody therapeutics address clinically-validated cancer targets in immuno-oncology, such as PD-L1, against which the clinical candidate CX-072 is directed, as well as novel targets, such as CD-166, that are difficult to drug without causing damage to healthy tissues.

Collaboration with large Strategic Partners

In addition to its proprietary programs, CytomX is collaborating with strategic partners including AbbVie, Bristol-Myers Squibb Company, Pfizer Inc., MD Anderson Cancer Center, and ImmunoGen, Inc. For more information, visit www.cytomx.com.

Current Price - $10.99 - Price Target of $22.33

Four major analysts are rating the stock as  strong buy with a price target of $22.33 compared to today's closing price of $10.99.

While we typically do not brag with "loud" headlines, but rather keep improving our services for your benefit, w e would like to point out that since inception two years ago, our "SWI Portfolio" and our
"SWI QuickPicks" have consistently outperformed all indices and many "Big-Firm" portfolios. We are frequently providing you with performance reports for both portfolios to provide full transparency and so that you can keep track of our performance.

If you want to follow all other companies that we cover with more in depth research reports, go to our research site at www.swiresearch.com/report-index to download the reports,
or visit
www.stockwatchindex.com for up to date news on the covered companies.
Please feel free to
re-distribute the Research Reports
and this Newsletter to your friends and colleagues.
Rainer Poertner - Chief Analyst
S tockWatchIndex  and SWI Research (SWI) are not registered investment advisers and the information  provided herein or any other SWI publication is not to be construed as personal financial advice, or a solicitation to buy or sell stock. SWI makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in its publications or on its web sites. Some of the published information has been provided by the companies covered, generated by publicly available sources, or what SWI deems to be reliable third party entities, but SWI does not guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or  warrant any results from use of the information. Readers are encouraged to consult their personal financial adviser before making any decisions to buy, sell or hold any securities mentioned herein. StockWatchIndex is not responsible for any error, mistake or shortcoming that may be occasioned at the time of publishing of the information in this publication, any other SWI publication, or its web sites and is not obligated to update and/or correct information. No liability is accepted by StockWatchIndex whatsoever for any direct, indirect or consequential loss arising from the use of the information. SWI expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information provided.  SWI has not been compensated for this report, may have acquired positions of stocks in this report for its portfolio a nd reserves the right to buy or sell positions at its sole  discretion. The included information is subject to change without notice. Please visit  www.swiresearch.com/#!legal-ease/lmvw1   for a full text of our Disclaimer, Privacy policy and Terms of Use.